Cargando…
Molecular biology of high-grade gliomas: what should the clinician know?
The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct molecular signatures that significantly impact treatment response and survival. Recent...
Autores principales: | Hofer, Silvia, Rushing, Elisabeth, Preusser, Matthias, Marosi, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905084/ https://www.ncbi.nlm.nih.gov/pubmed/24325789 http://dx.doi.org/10.5732/cjc.013.10218 |
Ejemplares similares
-
Biosimilars in rheumatology: what the clinician should know
por: Castañeda-Hernández, Gilberto, et al.
Publicado: (2015) -
Genetics of ADHD: What Should the Clinician Know?
por: Grimm, Oliver, et al.
Publicado: (2020) -
Apheresis: What Should a Clinician Know?
por: Parhofer, Klaus G.
Publicado: (2023) -
Infectious Scleritis: What the ID Clinician Should Know
por: Guerrero-Wooley, Richelle L, et al.
Publicado: (2018) -
Artificial intelligence in telemetry: what clinicians should know
por: Maslove, David M., et al.
Publicado: (2021)